Missoula, MT, February 26, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies for cancer, allergy, autoimmunity, and vaccines will attend the AAAAI meeting in San Diego from February 28-March 3 where Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on Inimmune’s clinical stage treatment for seasonal allergic rhinitis (https://annualmeeting.aaaai.org/).
Inimmune’s disease-modifying allergy treatment, INI-2004, is an allergen agnostic immunotherapy that binds and activates toll-like receptor 4 (TLR4). In response to the ragweed challenge, participants in our Phase I study treated with INI-2004 intranasally showed a dose-dependent improvement in nasal congestion as measured by acoustic rhinometry compared to placebo participants. Additionally, all doses of INI-2004 were well tolerated over multiple administrations.
Inimmune CEO, Dr. David Burkhart, noted that Rapid disease-modifying treatment for allergies are urgently needed and we are enthusiastic about positive Phase 1 Clinical Trial results with INI-2004.”
The AAAAI is a leading organization providing resources and education for allergists, immunologists, and patients across the spectrum of allergies, asthma, and related immune deficiency disorders. Their annual meeting beings together global experts in allergy and immunology to discuss the latest clinical advancements.
